Why are FTC serial-acquisition lawsuits and state mini-HSR laws breaking the private equity healthcare roll-up model?
Federal antitrust lawsuits targeting serial acquisitions alongside state mini-HSR pre-closing review laws are dismantling the private equity healthcare and veterinary roll-up model by blocking buyout sponsors from stealthily consolidating local medical clinics below federal Hart-Scott-Rodino reporting thresholds to extract regional monopoly pricing.
For over a decade, the classic private equity buy-and-build arbitrage relied on acquiring a platform practice in anesthesiology, dermatology, dental care, or veterinary medicine and executing dozens of bolt-on acquisitions valued under the $119.5 million HSR filing threshold. Once a sponsor captured dominant local market share, it used Management Services Organizations (MSOs) to hike out-of-network billing rates, execute real estate sale-leasebacks, and load the clinical entity with floating-rate debt to fund dividend recapitalizations. However, following the FTC's landmark enforcement actions against U.S. Anesthesia Partners and JAB Consumer Partners' veterinary clinic empire under Section 7 of the Clayton Act, serial roll-ups are now treated as unlawful creeping monopolies.
Even more damaging to buyout Internal Rates of Return (IRRs) is the wave of state-level ”mini-HSR” statutes and Corporate Practice of Medicine (CPOM) crackdowns enacted across California, Oregon, Illinois, New York, and Massachusetts. By empowering state Attorneys General to review, delay, or block sub-threshold healthcare M&A and outlawing MSO control agreements that interfere with clinical staffing, regulators have frozen the traditional multiple-expansion exit pathway. Will this federal and state antitrust offensive protect patients from debt-fueled medical price gouging, or will it starve independent physician and veterinary practices of vital growth capital?
Comentarios
Sé respetuoso. Los comentarios que reporten varias personas se ocultan hasta que los revise un moderador.
Para leer no necesitas cuenta; solo para comentar. Entras con un código que te llega al correo o con tu cuenta de Google. Mostramos solo el nombre que elijas; nunca tu correo.